Complete financial analysis of Hepion Pharmaceuticals, Inc. (HEPA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hepion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- New Energy Solar Limited (NEW.AX) Income Statement Analysis – Financial Results
- Hornby PLC (HRN.L) Income Statement Analysis – Financial Results
- CM Life Sciences II Inc. (CMIIW) Income Statement Analysis – Financial Results
- BH Macro Limited (BHMDF) Income Statement Analysis – Financial Results
- Gencell Ltd (GNCLF) Income Statement Analysis – Financial Results
Hepion Pharmaceuticals, Inc. (HEPA)
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 0.00 | 21.53K | 16.36K | 0.00 | 0.00 |
| Gross Profit | -67.13K | -77.46K | -86.07K | -34.52K | -26.74K | -18.79K | -21.94K | 0.00 | -21.53K | -16.36K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.64M | 33.27M | 20.40M | 12.00M | 3.18M | 7.59M | 14.33M | 13.65M | 15.02M | 8.40M | 314.25K | 734.56K |
| General & Administrative | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 7.28M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -583.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 6.69M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Other Expenses | 3.19M | 0.00 | 0.00 | 0.00 | -179.65K | -108.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.02M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Cost & Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.04M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.47K | 10.16K | 8.86K | 31.23K | 555.00K | 339.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 27.99K | 21.53K | 16.36K | 1.32K | 841.00K |
| EBITDA | -49.26M | -43.54M | -30.32M | -20.11M | -7.74M | -14.58M | -20.62M | -21.02M | -20.81M | -13.94M | -1.67M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.45M | -45.49M | -30.40M | -20.15M | -7.77M | -14.59M | -21.04M | -21.02M | -20.81M | -13.96M | -1.67M | -841.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -887.11K | 404.83K | -2.32M | -177.28K | -175.94K | 4.61M | 2.13M | 4.22M | 3.81M | -387.90K | -3.61M | -1.97K |
| Income Before Tax | -49.34M | -45.08M | -32.72M | -20.32M | -7.95M | -9.99M | -18.92M | -16.80M | -17.00M | -14.35M | -5.28M | -842.97K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 409.02K | -2.88M | 8.86K | 30.58K | -908.68K | -536.00K | -3.90M | -1.91M | -3.81M | 387.90K | 3.61M | -1.97K |
| Net Income | -48.93M | -42.20M | -32.72M | -20.35M | -7.04M | -9.45M | -15.02M | -14.89M | -17.00M | -14.35M | -5.28M | -842.97K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| EPS Diluted | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| Weighted Avg Shares Out | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.20K | 2.42K | 1.94K | 1.14K | 33.00K |
| Weighted Avg Shares Out (Dil) | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.21K | 2.42K | 1.94K | 1.14K | 33.00K |
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2020
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
CymaBay Therapeutics Inc. (CBAY) Q2 2020 Earnings Call Transcript | The Motley Fool
How Adam Smith Might Have Valued Amazon, Netflix, Tesla, And Tiny Biotechs (NASDAQ:AMZN)
Terns Pharmaceuticals Appoints Senthil Sundaram as Chief Executive Officer, Mark Vignola, Ph.D., as Chief Financial Officer, and Erin Quirk, M.D., as President
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript
Alnylam Managing Through Covid-19 Challenges And Executing Well (NASDAQ:ALNY)
Source: https://incomestatements.info
Category: Stock Reports